Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Drug Profile

Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Alternative Names: AQS 1302; AQS 1304; Cannabinoid transdermal delivery system; Clobazam transdermal patch

Latest Information Update: 28 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aequus Pharmaceuticals
  • Class Antidementias; Antiemetics; Antiepileptic drugs; Anxiolytics; Benzodiazepines; Cannabinoids; Picolines; Pyridines; Sedating antihistamines; Small molecules; Vitamins
  • Mechanism of Action Biogenic monoamine uptake modulators; Cannabinoid receptor modulators; GABA A receptor agonists; Histamine H1 receptor antagonists; Neurotransmitter stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Epilepsy; Nausea

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (Transdermal)
  • 28 Mar 2020 No recent reports of development identified for preclinical development in Epilepsy in Canada (Transdermal, Patch)
  • 28 Mar 2020 No recent reports of development identified for preclinical development in Nausea in Canada (Transdermal, Patch)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top